Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,387.05
(
0.29%
)
US TECH 100
22,494.80
(
-0.04%
)
Dow Jones
45,478.63
(
0.69%
)
Brent Oil
107.57
(
-0.63%
)
Bitcoin
67,485.32
(
2.32%
)
News Focus
News Focus
Post# of 257307
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122821
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 105259

Tuesday, 09/28/2010 3:25:01 PM

Tuesday, September 28, 2010 3:25:01 PM

Post# of 257307
IMGN is a reasonable choice, but my pick is ALNY. ALNY has in-licensed so much IP from third parties that any royalties they eventually keep on the 31 drug targets licensed to NVS will more than likely be de minimis. I wouldn’t be surprised if ALNY has to pass through 75%+ of gross royalties it earns from NVS.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today